{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:07:32Z","timestamp":1788962852590,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp; Disease"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of telbivudine (LdT), tenofovir alafenamide fumarate (TAF), and tenofovir disoproxil fumarate (TDF) for preventing hepatitis B transmission in immune\u2010tolerant pregnant women with HBV infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study involving women who had hepatitis B virus deoxyribonucleic acid (HBV DNA) \u2265 2\u2009\u00d7\u200910\n                      <jats:sup>5\u2009<\/jats:sup>\n                      IU\/mL\u00a0and initiated LdT, TDF, or TAF to prevent mother\u2010to\u2010child transmission (MTCT). The primary endpoint was the safety of mothers and infants. The secondary endpoints were maternal HBV DNA\u00a0reduction at delivery and MTCT rate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 96 patients were enrolled in the study (LdT group,\n                      <jats:italic>n\u2009<\/jats:italic>\n                      =\u200936; TDF group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200935; TAF group,\n                      <jats:italic>n\u2009<\/jats:italic>\n                      =\u200925). All infants received hepatitis B virus immunoprophylaxis. The MTCT rate was 0%([0 of 25] vs. [0 of 35] vs. [0 of 36],\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &gt;\u2009.05). No severe liver function damage occurred in any of the mothers. Babies delivered in all groups had prenatal ultrasound screening abnormalities, but abnormality rates were not statistically significant between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The application of TDF, TAF, or LdT to immune\u2010tolerant HBV\u2010infected pregnant women in middle\u2013late pregnancy\u00a0can successfully interrupt MTCT of the HBV virus. However, for all three groups of pregnant women who delivered babies with abnormal prenatal ultrasound screening, an expanded sample size may be needed for further observation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/iid3.1204","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T02:04:05Z","timestamp":1709085845000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the efficacy and safety of TAF, TDF, and LdT to prevent the transmission of hepatitis B in pregnant women: A retrospective study"],"prefix":"10.1002","volume":"12","author":[{"given":"Shufang","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases The Third Affiliated Hospital of Sun Yat\u2010Sen University  Guangzhou Guangdong Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases The Third Affiliated Hospital of Sun Yat\u2010Sen University  Guangzhou Guangdong Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfu","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases The Third Affiliated Hospital of Sun Yat\u2010Sen University  Guangzhou Guangdong Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-2267","authenticated-orcid":false,"given":"Chaoshuang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases The Third Affiliated Hospital of Sun Yat\u2010Sen University  Guangzhou Guangdong Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"World Health Organization WHO\u2010HIV\u20102016.06\u2010eng (EB\/OL). Accessed September 2019.http:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/ 2016"},{"key":"e_1_2_7_3_1","unstructured":"World Health Organization. (2021). July 27 Hepatitis B.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.015"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30593-4"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-019-05190-0"},{"issue":"4","key":"e_1_2_7_7_1","first-page":"496","article-title":"Efficacy and risk analysis of lamivudine and telbivudine in blockingmother\u2010to\u2010child intrauterine infection of hepatitis B virus","volume":"23","author":"Lei Zhao","year":"2020","journal-title":"J\u00a0Pract\u00a0Hepatol"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10026-0"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ped4.12205"},{"issue":"4","key":"e_1_2_7_11_1","first-page":"258","article-title":"Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune\u2010tolerant phase: a study of efficacy and safety of drug withdrawal","volume":"24","author":"Sheng QJ","year":"2016","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1508660"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.5223\/pghn.2020.23.4.311"},{"issue":"1","key":"e_1_2_7_14_1","first-page":"9","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2019","volume":"23","author":"Wang G","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10235-1"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2021.1936769"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.1204","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/iid3.1204","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.1204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:10:06Z","timestamp":1788959406000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.1204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1002\/iid3.1204"],"URL":"https:\/\/doi.org\/10.1002\/iid3.1204","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"value":"2050-4527","type":"print"},{"value":"2050-4527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2023-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1204"}}